BioNTech AG acquires EUFETS AG

09-Jun-2009 - Germany

BioNTech AG announced the acquisition of all shares of EUFETS AG from Fresenius Biotech GmbH (Munich, Germany). EUFETS, formerly a fully owned subsidiary of Fresenius Biotech GmbH, is a specialist in GMP and GLP services for innovative biopharmaceutical approaches. Under the new owner, EUFETS will retain all facilities, employees and contractual obligations of the former company.

"The investment in EUFETS is an excellent fit endowing BioNTech with synergistic platforms and complementary expertise" commented Prof. Dr. Ugur Sahin, CEO of BioNTech AG, and Dr. Klaus Kühlcke, vice president operations of EUFETS, adding, "We are interested to progress EUFETS into a center of excellence that addresses the needs of individualized medicine by developing and providing a wide range of high-quality GMP/GLP services for innovative approaches such as recombinant vaccines, cell based therapies, gene- and immunotherapies.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...